The authors thought that the therapy with VELCADE and tPA abolished the inactivation of fibrin/fibrinogen on NF-κB by directly inhibiting stroke-activated TLR2, TLR4, and IRAK1 and suppressing inflammatory respond [41]. The gene discussed is IRAK1; the disease is Stroke.